Tag: hyperkalemia
-
The clinical cost behind the finerenone headline — hyperkalemia, modest absolute benefit, and the real-world monitoring gap, by evidence tier
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. Behind finerenone’s headline hazard ratios sits a clinical cost that is not dramatic harm but friction. Across RCTs, hyperkalemia occurs at roughly 2× the placebo…
Uthando Nethemba 